Prognostic implication of early ventricular fibrillation among patients with ST elevation myocardial infarction.

Objective: The aim of this study was to analyze the prognosis of patients presenting early ventricular fibrillation (VF) in the setting of ST elevation myocardial infarction (STEMI).

Patients And Methods: Among patients included in the ARIAM (Análisis del Retraso en el Infarto Agudo de Miocardio) registry with the diagnosis of STEMI, those who received primary revascularization and were admitted in the first 12 h were analyzed retrospectively.

Results: From January 2007 to January 2012, 8340 patients were included in the STEMI cohort and 680 (8.

Safety and Efficacy of Prasugrel and Ticagrelor in Acute Coronary Syndrome. Results of a "Real World" Multicenter Registry.

Introduction And Objectives: The incorporation of the new antiplatelet agents (NAA) prasugrel and ticagrelor into routine clinical practice is irregular and data from the "real world" remain scarce. We aimed to assess the time trend of NAA use and the clinical safety and efficacy of these drugs compared with those of clopidogrel in a contemporary cohort of patients with acute coronary syndromes (ACS).

Methods: A multicenter retrospective observational study was conducted in patients with ACS admitted to coronary care units and prospectively included in the ARIAM-Andalusia registry between 2013 and 2015.

[Prosthetic valve thrombosis in a patient with antiphospholipid syndrome. Report of one case].

Primary antiphospholipid syndrome (APS) is a thrombophilic disorder not associated with connective tissue diseases or with autoimmune diseases. We report a 39-year-old female with a mechanical prosthetic mitral valve and a primary antiphospholipid syndrome. Anticoagulation with warfarin was changed for tinzaparine.